Status: Not yet recruiting
Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis
This Phase Ⅲ randomized, double-blind, active- and placebo-controlled trial aims to assess the efficacy and safety of Rupatifen Fumarate Capsules for seasonal allergic rhinitis. Eligible participants will be randomized to Rupatifen Fumarate Capsules, Rupatadine Fumarate Tablets (active comparator), or matching placebo. All treatments are administered once daily at a consistent time with a 24 ± 2-hour interval between doses for 2 consecutive weeks.
Participants needed: 550
Trial details
Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.Updated: Jul 17, 2026Locations: 8
Eligibility criteria
Aged from 18 to 65 years inclusive, no restriction on gender. [+4]
(Medical inquiry) Patients with asthma requiring long-term treatment (subjects w... [+18]